Overview: Free Insulin Bioactive TestIntroduction: The Free Insulin Bioactive Test measures free insulin to assess diabetes or insulin resistance, causing high blood sugar or fatigue. Aligned with 2023 ADA guidelines, it uses immunoassay for high specificity, supporting diabetes screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in biochemistry for patients with suspected diabetes or insulin resistance.
Other Names: Insulin Free Assay, Bioactive Insulin Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: Free insulin testing emerged in the 2000s with advanced diabetes research. Immunoassay-based methods improved diagnostic precision.
Purpose: Measures free insulin to diagnose diabetes or insulin resistance, guides treatment, and evaluates patients with high blood sugar or fatigue.
Test Parameters: 1. Free Insulin
Pretest Condition: Fasting 10-12 hours required. Collect serum or plasma. Report history of high blood sugar, fatigue, or diabetes symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document high blood sugar, fatigue, weight gain, or family history of diabetes. Include current medications, especially insulin.
Consent: Written consent required, detailing the tests purpose, diabetes implications, and risks of blood collection.
Procedural Considerations: Uses immunoassay to measure free insulin in serum or plasma. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for diabetes diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Non-fasting samples may reduce accuracy.
Clinical Significance: Elevated free insulin suggests insulin resistance or type 2 diabetes, guiding treatment. Normal levels may require further testing.
Specialist Consultation: Consult an endocrinologist for result interpretation and treatment planning.
Additional Supporting Tests: HbA1c, C-peptide, or glucose tolerance test to confirm diabetes or insulin resistance.
Test Limitations: Not specific to one condition; insulin levels vary with metabolic states. Clinical correlation is needed.
References: ADA Diabetes Guidelines, 2023; Diabetes Care, DeFronzo RA, 2022.
